Dongsung Pharmaceutical Co., Ltd.
KKRX:0022101,289.00
KRW
+29.00
(+2.30%)
ISIN
KR7002210003
Return %
Stock
S&P 500
1Y
32.48
14.39
3Y
-77.47
81.42
5Y
-85.90
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Won-gyun Na
- Full Time Employees
- 307
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Dongsung Building Seoul South Korea 01340
- IPO Date
- Jan 19, 1990
- Website
- dongsung-pharm.com
- Similar Companies
- Business
- Dong Sung Bio Pharm.Co.,Ltd. is a South Korean pharmaceutical company established in 1957 and headquartered in Seoul. The company specializes in the manufacture and sale of pharmaceuticals and cosmetics. Its pharmaceutical product portfolio includes over-the-counter (OTC) drugs such as emollients, vitamin supplements, alopecia treatments, antihistamines, liver disease treatments, antivirals, eye drops, menopause treatments, sleep inducers, antipyretics, analgesics, anti-inflammatories, vascular reinforcements, broad-spectrum skin disease treatments, gum disease treatments, blood circulation improvers, scar treatments, digestive aids, respiratory solvents, antifungal agents, as well as prescription drugs covering endocrine system treatments, corticosteroids, circulatory system drugs, psychotropic solvents, tumor therapies, antibiotics, and more. Additionally, the company offers hair dyes (including known brands like eZn), cosmetics, health functional supplements, nasal sprays, household items, muscle taping products, disinfectants, toothpaste, anti-hair loss shampoos, and sanitary napkins. Dong Sung Bio Pharm operates domestically in South Korea and exports products mainly to Southeast Asian markets and other international regions such as China, Japan, Singapore, Thailand, Taiwan, and the United States. In recent developments, Dong Sung Bio Pharm has made strides in health functional foods, particularly in developing innovative hangover remedies leveraging patents on compounds derived from fermented extracts of Hwangchil and Dangyuja, supported by government SME technology innovation funding. It has successfully passed clinical trials for its hangover relief product Haetgae Haechwi Good Morning, which is marketed domestically and exported. The company has formed strategic collaborations with research institutes and firms specializing in probiotics and health functional foods to secure scientific proof and extend its product offerings in functional health foods. Furthermore, Dong Sung Bio Pharm has been actively expanding its beauty segment both at home and overseas through distribution agreements, such as the recent contract with Indonesian retailer OH. Notably, the company has undergone management changes and applied to terminate court rehabilitation proceedings amid a corporate control dispute, asserting its capacity to repay debts and positioning for potential mergers and acquisitions to strengthen business continuity. Overall, Dong Sung Bio Pharm operates within the drug manufacturing and healthcare sector with a diversified portfolio encompassing pharmaceuticals, cosmetics, health supplements, and personal care products, backed by a history of over 68 years and continuous innovation efforts in medical and functional food markets. It maintains significant research collaborations aimed at advancing therapies such as photodynamic therapy for cancer and expanding product lines into nutraceuticals and beauty care solutions globally. The company employs around 290 people and stays committed to quality control and high standards under its corporate philosophy centered on health from nature.